Extendicare Inc. (TSE:EXE - Get Free Report) declared a quarterly dividend on Wednesday, August 6th, RTT News reports. Shareholders of record on Friday, August 29th will be paid a dividend of 0.042 per share on Monday, September 15th. This represents a c) annualized dividend and a yield of 1.3%.
Extendicare Stock Down 0.2%
Extendicare stock traded down C$0.03 on Wednesday, hitting C$12.66. 174,945 shares of the stock traded hands, compared to its average volume of 185,051. The company has a current ratio of 0.62, a quick ratio of 0.98 and a debt-to-equity ratio of 283.02. The firm has a market cap of C$1.06 billion, a P/E ratio of 16.14 and a beta of 1.26. The business's fifty day simple moving average is C$13.57 and its 200 day simple moving average is C$12.97. Extendicare has a 1 year low of C$7.49 and a 1 year high of C$15.24.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on EXE shares. National Bankshares set a C$15.40 price objective on Extendicare and gave the company an "outperform" rating in a research report on Thursday, July 17th. National Bank Financial upgraded Extendicare to a "strong-buy" rating in a report on Wednesday, July 16th. BMO Capital Markets raised their price target on Extendicare from C$13.50 to C$14.50 in a report on Monday, May 12th. Finally, TD Securities raised their price target on Extendicare from C$13.00 to C$15.00 and gave the company a "hold" rating in a report on Thursday, May 22nd. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of C$13.98.
View Our Latest Analysis on Extendicare
About Extendicare
(
Get Free Report)
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Extendicare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.
While Extendicare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.